Raymond Chung

Raymond Chung leads research on the residual risk of hepatocellular carcinoma following HCV eradication with direct-acting antiviral therapy. His studies have characterized the persistent HCC risk in patients with pre-existing cirrhosis even after achieving virologic cure, establishing the rationale for lifelong HCC surveillance in this population. He has investigated biomarkers that predict HCC development in HCV patients post-SVR and characterized immune and fibrotic features of the liver that persist after viral clearance. His clinical guidance on HCC surveillance in viral hepatitis patients has influenced international hepatology society guidelines.